GB1565209A - Clavulanic acid derivatives - Google Patents

Clavulanic acid derivatives Download PDF

Info

Publication number
GB1565209A
GB1565209A GB4189775A GB4189775A GB1565209A GB 1565209 A GB1565209 A GB 1565209A GB 4189775 A GB4189775 A GB 4189775A GB 4189775 A GB4189775 A GB 4189775A GB 1565209 A GB1565209 A GB 1565209A
Authority
GB
United Kingdom
Prior art keywords
compound
group
composition
etherifying
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4189775A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Priority to GB4189775A priority Critical patent/GB1565209A/en
Priority to IE2047/76A priority patent/IE44295B1/en
Priority to ZA765560A priority patent/ZA765560B/en
Priority to ZM11776A priority patent/ZM11776A1/en
Priority to IL50514A priority patent/IL50514A/en
Priority to AU18033/76A priority patent/AU512859B2/en
Priority to PT65622A priority patent/PT65622B/en
Priority to PH18946A priority patent/PH16904A/en
Priority to NZ182046A priority patent/NZ182046A/en
Priority to SE7611045A priority patent/SE440080B/en
Priority to BE171322A priority patent/BE847045A/en
Priority to AT753376A priority patent/AT352873B/en
Priority to FR7630455A priority patent/FR2327776A1/en
Priority to GR51905A priority patent/GR61645B/en
Priority to CA263,105A priority patent/CA1081699A/en
Priority to CH1290176A priority patent/CH629207A5/en
Priority to RO7687984A priority patent/RO69458A/en
Priority to SU762408252A priority patent/SU656523A3/en
Priority to DK457476A priority patent/DK457476A/en
Priority to LU75980A priority patent/LU75980A1/xx
Priority to HU76BE1340A priority patent/HU175574B/en
Priority to NO763473A priority patent/NO763473L/no
Priority to DE19762646004 priority patent/DE2646004A1/en
Priority to FI762908A priority patent/FI64162C/en
Priority to JP51122725A priority patent/JPS5268195A/en
Priority to DD195243A priority patent/DD127630A5/xx
Priority to HU76BE1271A priority patent/HU173804B/en
Priority to YU02516/76A priority patent/YU251676A/en
Priority to BG7634436A priority patent/BG35466A3/en
Priority to ES452362A priority patent/ES452362A1/en
Priority to PL21090176A priority patent/PL117561B1/en
Priority to NL7611286A priority patent/NL7611286A/en
Priority to AR265081A priority patent/AR213828A1/en
Priority to ES464123A priority patent/ES464123A1/en
Priority to ES464122A priority patent/ES464122A1/en
Priority to AT915178A priority patent/AT362504B/en
Priority to AT915078A priority patent/AT362503B/en
Priority to US06/008,421 priority patent/US4228174A/en
Priority to CA338,869A priority patent/CA1077843A/en
Publication of GB1565209A publication Critical patent/GB1565209A/en
Priority to SE8005662A priority patent/SE8005662L/en
Priority to SE8005661A priority patent/SE8005661L/en
Priority to SE8005663A priority patent/SE8005663L/en
Priority to DK370780A priority patent/DK370780A/en
Priority to DK370680A priority patent/DK370680A/en
Priority to US06/278,564 priority patent/US4609495A/en
Priority to KE3292A priority patent/KE3292A/en
Priority to US06/538,767 priority patent/US4548815A/en
Priority to NO833841A priority patent/NO833841L/en
Priority to NO833842A priority patent/NO833842L/en
Priority to HK489/83A priority patent/HK48983A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

(54) CLAVULANIC ACID DERIVATIVES (71) We, BEECHAM GROUP LIMITED, a British Company of Beecham House, Great West Road, Brentford, Middlesex, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:- The present invention relates to p-lactam containing compounds, to their preparation and to compositions containing them.
British Patent Specification Nos. 1508977 and 1508978 (see also Belgian Patent Specification No. 827926) disclose inter alia clavulanic acid and its salts and esters, which substance clavulanic acid has the formula (I):
Clavulanic acid and its salts and esters are able to inhibit p-lactamases from a range of bacteria and owing to this useful property are able to enhance the effectiveness of penicillins and cephalosporins against many gram-positive and gram-negative bacteria. It has now been discovered that certain derivatives of clavulanic acid also possess useful anti-bacterial and p-lactamase inhibitory activity.
Accordingly the present invention provides ethers of the formula (ill):
and salts and esters thereof wherein R is an inert etherifying organic group of up to 18 carbon atoms.
The terms "inert" and "inertly substituted" herein means that the moiety to which the term refers is not unstable. It will be appreciated that a chemically unstable compound is inappropriate for use as a medicinal agent in the treatment of bacterial infections.
Aptly the compound of the formula (II) is of the formula (III):
wherein CH2R1 is an inert etherifying group R as defined in relation to formula (11).
Suitable groups R for inclusion in the compounds of the formula (II) include hydrocarbon groups such as alkyl, alkenyl or alkynyl group or such groups substituted by a phenyl group. Other suitable groups include hydrocarbon groups inertly substituted by a halogen atom or a OR2 group, a OH group, a O.CO. R2 group, a CO2R2 group, a NR3COR2 group, a NR3CO2R2 group, a SOR2 group, a SO2R2 group, a CO2R2 group, a NH2 group, a NR2R3 group, a NO2, a C N group or a CONR2R3 group wherein R2 is a hydrocarbon group of up to 8 carbon atoms and R3 is a hydrocarbon group of up to 4 carbon atoms. Favoured values for the R2 groups include the methyl, ethyl, propyl, butyl, phenyl and benzyl groups. A preferred value for the R2 group is the methyl group. A preferred value for the R3 group is the methyl group.
An apt value for R is the methyl group. Other favoured values for R include the groups of the formula CH2R1 where R' is an alkyl group of 1 to 4 carbon atoms, which is to say R1 is favourably a methyl, ethyl, propyl or butyl group. Further favoured values for R are those of the formula CH2R1 where R1 is a phenyl group or a naphthyl group or a phenyl group substituted by a halgen or a group R4 or OR4 wherein R4 is a methyl, ethyl or propyl group. Such compounds have good antistaphyloccocal activity.
Other suitable values for R are those of the formula -CH2-X-CO2H and -CH2-X-C02R5 wherein X is a bond or CH2 and R5 is a methyl, ethyl, propyl or butyl group or a methyl, ethyl, propyl or butyl group substituted by a phenyl group.
Further suitable values for R are those of the formula -CH2-Y-NR6R7 wherein -CH2-Y- is an alkylene group of 2 to 4 carbon atoms or an alkylene group of 2 to 4 carbon atoms substituted by a phenyl group; R6 is a hydrogen atom or a methyl, ethyl, propyl or butyl group; and R7 is a hydrogen atom or a group R8, COR8 or CO2Rs wherein R8 is a methyl, ethyl, propyl or butyl group or a methyl, ethyl, propyl or butyl group substituted by a phenyl group. Aptly Y is a CH2 group.
Aptly R6 is a methyl. Aptly R7 is a hydrogen atom. Aptly R7 is a benzyloxycarbonyl group.
Other values of R worthy of mention include the ethoxycarbonylmethyl benzyloxycarbonylmethyl, carboxymethyl, cyanomethyl, p-nitrobenzyl, allyl, 2benzyloxycarbonylethyl, 2-carboxyethyl, acetonyl, 4-chlorophenacyl, 3hydroxypropyl and 2-(N-benzyloxycarbonyl-N-methylamino)ethyl groups.
The compounds of this invention are suitably provided as the acid or more suitably as a salt which, since the compounds of this invention are intended for pharmaceutical use, is normally a pharmaceutically acceptable salt. Suitable pharmaceutically acceptable salts include the sodium, potassium, calcium and magnesium salts. Other suitable salts include the lithium, ammonium and conventional substituted ammonium salts such as monoalkylamine, dialkylamine, trialkylamine (for example trimethylamine or triethylamine) or quaternary ammonium salts.
The compounds of this invention may be provided in the form of an ester.
Suitable esters include those of the formulae (IV) and (V):
wherein R is as defined in relation to formula (II) and A' is an alkyl group of 1 to 8 carbon atoms optionally substituted by halogen or a group of the formula OA4, OCOA4, SA4 or SO2A4 wherein A4 is a hydrocarbon group of up to 6 carbon atoms; A2 is a hydrogen atom, an alkyl group of up to 4 carbon atoms or a phenyl group optionally substituted by halogen or by a group A5 or OA5 where As is an alkyl group of up to 6 carbon atoms; and A3 is a phenyl group optionally substituted by halogen or by a group As or OA5 where A5 is an alkyl group of up to 6 carbon atoms.
An apt value for A' is the methyl group. An apt value for CHA2A3 is the benzyl group.
The esters within this invention are preferably in vivo hydrolysable. Suitable esters include those described in Belgian Patent Specification No. 827926 as being in vivo hydrolysable when attached to clavulanic acid. Particularly suitable in vivo hydrolysable ester forming groups include acetoxymethyl, a-acetoxyethyl, pivaloyloxymethyl, phthalidyl, ethoxycarbonyloxymethyl and aethoxycarbonyloxyethyl.
Compounds worthy of mention include 9-O-methylclavulanic acid and its pharmaceutically acceptable salts and esters. Suitable esters of 9-0methylclavulanic acid include its methyl and benzyl esters. Suitable pharmaceutically acceptable salts of 9-O-methylclavulanic acid include the sodium, potassium, calcium and magnesium salts.
The present invention also provides pharmaceutical compositions which comprise a compound of this invention and a pharmaceutically acceptable carrier therefor.
The compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of infection in mammals, including humans.
Suitable forms of the compositions of this invention include tablets, capsules, creams, syrups, suspensions, solutions, reconstitutable powders and sterile forms suitable for injection or infusion. Such compositions may contain conventional pharmaceutically acceptable materials such as diluents, binders, colours, flavours, preservatives and disintegrants in accordance with conventional pharmaceutical practice in the manner well understood by those skilled in the art of formulating antibiotics.
In jectable or infusable compositions of salts of a compound of the formula (II) are particularly suitable as high tissue levels of a compound of the formula (II) can occur after administration by injection or infusion. Thus, one preferred composition aspect of this invention comprises a salt of a compound of the formula (II) in sterile form.
Unit dose compositions comprising a compound of the formula (II) or a salt or ester thereof adapted for oral administration form a further preferred composition aspect of this invention.
The compound of the formula (II) or its pharmaceutically acceptable salt or ester may be present in the composition as sole therapeutic agent. However, the compound of the formula (II) or its pharmaceutically acceptable salt or ester may favourably be present with a penicillin or cephalosporin. Suitable penicillins for inclusion in such synergistic compositions include benzylpenicillin, phenoxymethylpenicillin, propicillin, ampicillin, amoxycillin, epicillin, cyclacillin, hetacillin, metampicillin or the acetoxymethyl, pivaloyloxymethyl or phthalidyl esters of benzylpenicillin, ampicillin or amoxycillin or the phenyl, tolyl or indanyl a-esters of carbenicillin or ticarcillin. Other penicillins suitable for inclusion in such compositions include ticarcillin and carbenicillin. Suitable cephalosporins for use in such compositions include cephaloridine, cephalothin, cefazolin, cephalexin, cephacetrile, cephradine, cephapirin and cephaloglycine. Such penicillins and cephalosporins may be used in the form of their pharmaceutically acceptable salt or hydrate.
Naturally if the penicillin or cephalosporin present in the composition is not suitable or oral administration then the composition will be adapted for parenteral administration.
When in a pharmaceutical composition together with a penicllin or cephalosporin the weight ratio of a compound of the formula (II) or its pharmaceutically acceptable salt or ester present to penicillin or cephalosporin present may vary over a wide range of ratios, for example 10:1. Aptly a ratio between 3:1 and 1:3 may be used; advantageously this may be a ratio such as 1:2 or 1:1.
The total quantity of antibacterial agents present in any unit dosage form will normally be between 50 and 1500 mg and will usually be between 100 and 1000 mg.
Compositions of this invention may be used for the treatment of bacterial infections of mammals excluding humans, e.g. of, inter alia, the respiratory tract, the urinary tract and soft tissues and mastitis in cattle.
Normally between 50 and 3000 mg of the compounds of the invention will be administered each day of treatment but more usually between 100 and 1000 mg of the compounds of the invention will be administered per day, for example as I to 6 doses, more usually 2 to 4 doses.
The penicillin or cephalosporin in synergistic compositions of this invention will normally be present by up to or at approximately the amount at which it is conventionally used.
Particularly favoured compositions of this invention will contain from 1501000 mg of amoxycillin, ampicillin or a pro-drug therefor and from 50500 mg of a compound of the formula (II) or a salt or in vivo hydrolysable ester thereof and more suitably from 200-500 mg of amoxycillin, ampicillin or a pro-drug therefor and from 50250 mg of a compound of the formula (II) or a salt or in vivo hydrolysable ester thereof.
The materials present in such compositions may be hydrated, if required, for example ampicillin trihydrate or amoxycillin trihydrate may be employed. The weights of the antibiotics in such compositions are expressed on the basis of antibiotic theoretically available from the composition and not on the basis of the weight of pro-drug.
The present invention also provides a process for the preparation of a compound of the formula (II) as hereinbefore defined which process comprises the etherification of an ester of clavulanic acid and thereafter if desired cleaving a thus formed ester of the compound of the formula (II) by hydrogenolysis or hydrolysis to yield the compound of the formula (II) or its salt.
The preferred method of preparing esters of the compound of the formula (II) is by the reaction of the ester of clavulanic acid and a diazo compound.
Normally this diazo process will be adapted to the preparation of an ester of a compound of the formula (III) by the reaction of an ester of clavulanic acid with a diazoalkane of the formula N2-CHR1.
Naturally any reactive moiety present in the diazo compound, such as an amino, carboxylic or hydroxyl group, is protected during a condensation reaction in a conventional manner such as protection with a benzyloxycarbonyl group for the amino or hydroxyl group and benzyl group for the carboxyl group. Such protecting groups may be removed by hydrogenation in conventional manner thereafter.
The reaction with the diazo compound will suitably take place in the presence of a Lewis acid catalyst such as boron trifluoride, for example as boron trifluoride etherate. Suitably the reaction takes place in a solvent such as tetrahydrofuran, methylene chloride, methanol, chloroform or dioxane. The reaction normally takes place at a depressed or non-elevated temperature, for example -80" to +30"C, and preferably at a depressed temperature, for example 30a to +100C. A convenient temperature for carrying out the reaction is about -20"C to 0 C.
Esters of the compound of the formula (II) may also be prepared by the reaction of alcohol of the formula ROH where R is as defined in relation to formula (II) with the corresponding ester of clavulanic acid in the presence of a Lewis acid catalyst such as boron trifluoride or its equivalent, for example as BF3 . O(C2H5)2.
The preceding reaction normally takes place in a solvent inert under the reaction conditions such as chloroform, dichloromethane, tetrahydrofuran or dioxane at a depressed or non-elevated temperature, for example -80"C to +300C, and preferably at a depressed temperature, for example -500C to OOC. and conveniently at about -30"C.
An alternative form of this method of preparation of esters of the compounds of the formula (II) comprises the reaction in the presence of a Lewis acid of an alcohol of the formula ROH wherein R is as defined in relation to formula (II) with the corresponding ester of an acylated derivative of clavulanic acid wherein the 9position hydroxyl group is acylated so as to be of the sub-formula O . CO . R9 wherein R9 is a C16 alkyl group optionally inertly substituted by one or more halogen atoms.
The conditions for this reaction are similar to those outlined above for the reaction of the alcohol ROH with an ester of clavulanic acid.
The acylated compounds may be prepared as described in Belgian Patent No.
834645, that is by the reaction of a compound of the formula R9 . CO2H or a reactive acylating derivative thereof with the corresponding ester of clavulanic acid.
Salts of the compound of the formula (II) may be prepared from esters of the compound of the formula (II) by very mild basic hydrolysis, for example by hydrolysis in an aqueous solution maintained at pH 7 to 9 by the slow addition of base.
The compounds of the formula (II) and salts thereof may be prepared from hydrogenolysable esters of compounds of formula (II) by hydrogenation, e.g. using a medium or low pressure of hydrogen in the presence of a transition metal catalyst.
Palladium, for example 10% palladium on charcoal, has proved a particularly useful catalyst. We have found that a suitable ratio for the weight of 10 palladium on charcoal used to the weight of ether used is 1:3.
The hydrogenation reaction preferably occurs in a solution in a solvent which consists of or contains tetrahydrofuran.
Suitable hydrogenolysable esters include those of the formula (V) as hereinbefore defined. A preferred hydrogenolysable ester is the benzyl ester. A preferred hydrolysable ester is the methyl ester.
If a base such as sodium hydrogen carbonate, potassium hydrogen carbonate, lithium carbonate or calcium carbonate is included in the reaction mixture then the resulting compound is in the form of a salt. If no such base is included the product is in the form of the free acid.
Acids of the formula (II) may also be prepared by the careful acidification of the corresponding sodium or like salt.
From the preceding comments it will be appreciated that this invention provides a process for the preparation of the compounds of the formula (II) or a salt thereof which process comprises the de-esterification of an ester of a corresponding compound of the formula (II).
Esters of the compounds of the formula (II) may be prepared by the reaction of a salt of a compound of the formula (II) such as an alkali metal salt with an esterifying agent such as a halide or active ester such as a chloride, bromide, iodide, methanesulphonate or toluenesulphonate or by reaction of an acid of the formula (II) with a diazocompound. Such reactions proceed under conventional conditions.
Thus the present invention provides a process for the preparation of esters of the compounds of the formula (II) which process comprises the esterification of the corresponding compound of the formula (II) or a salt thereof.
Normally and preferably the processes of this invention are adapted to prepare those compounds of the formula (II) as hereinbefore described as being preferred compounds of this invention.
The esters of the compounds of the formula (II) may also be prepared by the etherification of the corresponding ester of clavulanic acid by reaction with a compound of the formula R-Q wherein Q is a group readily displaceable by an electron-rich moiety.
Suitably Q is a chlorine, bromine or iodine atom. Most suitably Q-R is a group of the formula Q-CH2R1 where R' is as hereinbefore defined.
Normally the reaction is carried out in the presence of an acid acceptor such as collidine or dicyclohexylamine.
IThe preparation of diazo compounds is described in Houben-Weyl, Methoden der Organischen Chemie, Vol 10/4. 4th Edition.l The following Examples are illustrative of the invention: Example 1 Preparation of Methyl 9-O-methylclavulanate
Benzyl clavulanate (el) (1.5 g) in methanol (10 ml) was hydrogenated over 10% palladium on charcoal (0.4 g) for - hour at ambient temperature and pressure. The solution was filtered through Celite (Registered Trade Mark) and treated with a solution of diazomethane in ether at 0 C. The solution was left at 0 C overnight, the solvent evaporated and the oil chromatographed on silica gel to yield as the second eluted product crude (e2) (35 mg). Re-chromatography provided the title product as a colourless oil (15 mg).
I.r. (CHCI3): 1800, 1750, 1695 cm-'; N.m.r. (CDCl3): 3.03 (1H, dd, J 17Hz, J' 1Hz, 6 -CH), 3.53 (1H, dd, J 17Hz, J' 2.5Hz, 6sr-CH), 3.31 (3H, s, OCH3), 3.79 (3H, s, CO2CH3), 4.03 (2H, d, J 7Hz, CH2OCH3), 4.88 (1H, brt. J 7Hz, olefinic CH), 5.08 (1H, m, 3-CH), 5.70 8 (1H, dd, J 2.5Hz, J' 2.5Hz, 5-CH).
The approximate -lactamase inhibition Iso values in ,figiml for (e2) were as follows: Escherichia coli JT4 0.9 Klebsiella aerogenes E70 0.25 Staphylococcus aureus Russell 0.5 Escherichia coli JT410 3.1 P. moig, Cr. 0.68 Pseudomonas aeruginosa 1.9 Citrobacter mantio 0.45 Example 2 Preparation of Benzyl 9-O-methylclavulanate
Benzyl clavulanate (el) (300 mg) was dissolved in dry methylene dichloride (25 ml) and cooled to 0 C. Boron trifluoride etherate (5 drops) was added at 0 C, followed by a solution of diazomethane in ether. The reaction mixture was stirred at 0 C for one hour and washed with 3% sodium bicarbonate solution (2x25 ml).
The organic phase was dried over magnesium sulphate and evaporated; chromatographic purification gave the title compound (e3) (66 mg).
I.r. (CHCI3): 1800, 1745, 1695 cm-'; N.m.r. (CDCl3): 3.10 (1H, d, J 17Hz, 6pCH), 3.35 (3H, s, OCH3), 3.60(1H, dd, J 17Hz, J' 2.5Hz, 6α-CH), 4.12 (2H, d, J 8Hz, CH2OCH3), 4.94 (1H, t, J 8Hz, =CH-CH2), 5.24 (1H, br.s, 3-CH), 5.32 (2H, s, CO2CH2Ph), 5.82 (1H, d, J 2.5Hz, 5-CH), 7.51 8 (5H, s, CO2CH2Ph).
The approximate -lactamase inhibition I50 values in ,ig/ml for (e3) were as follows: Escherichia coli JT4 0.1 Klebsiella aerogenes E70 0.05 Staphylococcus aureus Russell 0.05 Proteus mirabilis C889 < 0.07 Pseudomonas aeruginosa 1.4 Pseudomonas dalgleish < 0.07 Citrobacter mantio 1.1 Example 3 Preparation of Sodium 9-O-methylclavulanate
The ether (e3) (30 mg) was dissolved in tetrahydrofuran (3 ml) and 100 palladium on charcoal (10 mg) added. The solution was hydrogenated at ambient temperature and pressure for 15 minutes, filtered and sodium bicarbonate (8.4 mg) in 0.5 ml water was added. The solvent was evaporated to yield the sodium salt (e4) as an amorphous solid after trituration with ether (15 mg).
I.r. (KBr disc): 1790, 1690, 1615 cm-': N.m.r. (D2O): 3.07(1H, d, J 17Hz, 6 -CH), 3.27 (3H, s, OCH3), 3.54(1H, dd, J 17Hz, J' 2.5Hz, 6a-CH), 4.04 (2H, d, J 8Hz, CH2OCH3), 4.87(1 H, t, J 8Hz, =CH-CH2), 4.93 (1H, s, 3-CH), 5.69 S (lH, d, J 2.5Hz, 5-CH).
The approximate plactamase inhibition 150 values in ,ug/ml for (e4) were as follows: Escherichia coli JT4 0.18 Klebsiella aerngenes E70 0.07 Staphylococcus aureus Russell 0.05 Proteus mirabilis C889 0.01 Example 4 Preparation of Methyl 9-O-benzylclavulanate
Benzyl clavulanate (el) (300 mg) in methylene chloride (25 ml) was cooled to -30 C and treated with boron trifluoride etherate (5 drops), followed by a solution of diazotoluene in ether. The solution was stirred at -300C for one hour and washed with 3% sodium bicarbonate solution (3x25 ml). The organic phase was dried over magnesium sulphate and evaporated to yield after chromatography crude benzyl 3 - (2 - benzyloxyethylidene) - 7 - oxo - 4 - oxa - 1 - aza bicyclo[3,2,0]heptane - 2 - carboxylate (e5) (150 mg) as an oil. The oil was dissolved in tetrahydrofuran (5 ml) and hydrogenated at ambient temperature and pressure over 10% Pd/C (20 mg) for 20 minutes. The solution was filtered and treated with a solution of diazomethane in ether at OOC. Evaporation of the solvent and chromatography provided the title product (e5) (30 mg) as a colourless oil.
I.R. (CHCl3): 1800, 1750, 1695 cm-': N.m.r. (CDCl3): 3.12 (IH, d, J 17Hz, 6 -CH), 3.62 (1H, dd, J 17Hz, J' 2.5Hz, 6a-CH), 3.89 (3H, s, CO2C 4.25 (2H, d, J 8Hz, =CH-CH2O), 4.61 (2H, s, OCH2Ph), 5.02(1H, br.t., J 8Hz, =CH-CH2), 5.18(1H, m, 3-CH), 5.82 (1H, d, J 2.5Hz, 5-CH), 7.49 a (5H, s, OCH2Ph); [al020=+150 (c=1.37; MeOH).
Antibacterial Activity In Vitro (,ug/ml) Staphylococcus aureus Oxford 15-31 Staphylococcus aureus Russell 8-15 Klebsiella aerogenes A. > 500 , Lactamase Inhibition Iso (g/m1) Escherichia coli JT4 0.8 Klebsiella aerogenes E70 0.8 Staphylococcus aureus Russell 0.005 Example 5 Preparation of Sodium 9-O-benzylclavulanate
Crude benzyl clavulanate (e 1) (150 mg) was dissolved in tetrahydrofuran (5 ml) and hydrogenated at ambient temperature and pressure over 10% Pd/C (20 mg) for 20 minutes. The solution was filtered and treated with sodium bicarbonate (15 mg) in 1 ml water. The solvent was evaporated and the residue taken up in water (10 ml) and washed with ethyl acetate (3x 10 ml). The aqueous phase was evaporated to yield the required sodium salt as an amorphous solid after trituration with ether (e6) (35 mg).
I.r. (KBr): 1790, 1690, 1615 cm-t; N.m.r. (D2O): 3.09 (1H, d, J 17Hz, 6CH), 3.59(1H, dd, J 17Hz, J@ 2.5Hz, 6a- CH), 4.20 (2H, d, J 8Hz, =CH-CH3O), 4.48 (2H, s, OCH2Ph), 4.97 (IH, br.t., J 8Hz, =CH-CH2O), 4.99 (IH, m, 3-CH), 5.74 (1H, d, J 2.5Hz, 5 CH), 7.42 a (5H, s, OCH2Ph); [&alpha;]D20=+22.5 (c=1.15; 50 aqueous MeOH).
Antibacterial Activity In Vitro (,uzg/ml) Klebsiella aerogenes A. 125 Staphylococcus aureus Oxford 4.0 Staphylococcus aureus Russell 8.0 A-Lactamase Inhibition I50( g/ml) Escherichia coli JT4 0.1 Klebsiella aerogenes E70 0.04 Staphylococcus aureus Russell 0.005 Proteus mirabilis C889 0.02 Pseudomonas dalgleish 0.008 Example 6 Preparation of Benzyl 9-O-(ethoxycarbonylmethyl)clavulanate
Benzyl clavulanate (el) (1.44 g) was dissolved in dry methylene dichloride (100 ml) and boron trifluoride etherate (25 drops; 0.3 ml) was added at -300C. Ethyl diazoacetate (2.90 g; 5 equivalents) in methylene dichloride (10 ml) was added dropwise over half an hour and the mixture stirred at -300C to -100C for one hour.
The solution was washed with 3 / sodium bicarbonate solution (3x50 ml) and dried over magnesium sulphate. The solvent was evaporated at room temperature and the residue chromatographed to yield the title compound (e7) as a colourless oil (600 mg).
I.r. (CHCl3): 1800, 1745, 1695 cm-'; N.m.r. (CDCl3): 1.29 (3H, t, J 8Hz, -CO2CH2CH3), 3.00 (1H, d, J 17Hz, 6P- CH), 3.50 (1H, dd, J 17Hz, J' 2.5Hz, 6a-CH), 3.97 (2H, s, CH2CO2Et), 3.90 to 4.50 (4H, complex pattern, =CH-CH2 and CO2CH2CH3, 4.79(1H, t, J 8Hz, =CH-CH2), 5.14 (1H, brs, 3-CH), 5.23 (2H, s, CO2CH2Ph), 5.72 (1H, d, 2.5Hz, 5-CH), 7.37 # (5H, s, CO2CH2Ph).
[&alpha;]D21=+35.3 (c=1.29; MeOH).
The approximate ,B-lactamase inhibition 15o values in ,ug/ml for (e7) were as follows: Escherichia coli JT4 0.14 Klebsiella aerogenes E70 0.30 Staphylococcus aureus Russell 0.12 Proteus mirabilis C889 1.0 Antibacterial Activity In Vitro (,ug/ml) Klebsiella aerogenes A. > 500 Staphvlococcus aureus Oxford 125 Staphylococcus aureus Russell 125 Example 7 Preparation of Sodium 9-O-(ethoxycarbonylmethyl)clavulanate
The ester (e7) (188 mg) was dissolved in dry tetrahydrofuran (5 ml) and 10% Pd/C (65 mg) was added. The solution was hydrogenated at ambient temperature and pressure for fifteen minutes, the solution filtered through kieselguhr and sodium bicarbonate (42 mg) in water (1 ml) was added. The solvent was evaporated and the residue chromatographed on silica gel, eluting with butanol/ethanol/water, 4/1/1. Trituration of the product with ether gave the sodium salt as an amorphous solid (e8) (95 mg).
I.r. (KBr): 1790, 1740, 1690, 1600 cm-l; N.m.r. (D2O): 1.27 (3H, t, J 8Hz, CO2CH2CH3), 3.09 Benzyl clavulanate (el) (1.8 g) was dissolved in dry methylene chloride (100 ml) and boron trifluoride etherate (25 drops; 0.3 ml) was added at 300 C. Benzyl diazoacetate (5 g of 66% pure material) in methylene chloride (20 ml) at -300C was added dropwise over half an hour and the mixture stirred at -300C to -10"C for one hour. The solution was washed with 3% sodium bicarbonate solution (2x50 ml) and dried over magnesium sulphate. The solvent was evaporated at room temperature and the residue chromatographed over silica gel, eluting with hexane/ethyl acetate. The resulting somewhat impure oil was rechromatographed to yield pure title material (e9) as a colourless oil (0.32 g).
I.r. (film): 1800, 1760, 1750, 1695 cm-'; N.m.r. (CDCl3): 7.29 (10H, aromatic H), 5.58 (liy, d, J 2.5Hz, 5-CH), 5.13 (4H, CH2Ph), 5.03 (1H, 3-CH), 4.79 (liy, t, J 7Hz, =CH-CH2), 4.16 (2H, d, j 8Hz, =CH-CH2-), 4.00 (2H, s, --CH-CH2-O-CH-), 3.402.95 a (2H, dd, J 18Hz, 6-CH2).
The benzyl diazoacetate was prepared by the reaction of benzyl chloroformate and diazomethane at 4 C for 3 days which yielded a 66 /" pure product as an oil.
Example 10 Preparation of Di-sodium 9-O-(carboxymethyl)clavulanate
The ester (e9) (260 mg) was dissolved in a mixture of tetrahydrofuran and water (5:1, 12 ml) and sodium bicarbonate (100 mg) and 10% Pd/C (150 mg) were added. The solution was hydrogenated at ambient temperature and pressure for 30 minutes, filtered and evaporated to yield the desired disodium salt (elO).
I.r. (KBr): 1780, 1685, 1600, 1425 cm-'.
Example 11 Preparation of Benzyl 9-O-(cyanomethyl)clavulanate
A solution of benzyl clavulanate (el) (5.18 g) in methylene dichloride (50 ml) was dried over 4A molecular sieves and filtered. The solution was cooled to -40 - -300C and 1 ml boron trifluoride etherate was added. A solution of diazoacetonitrile (prepared from aminoacetonitrile hydrochloride (9.3 g) as in Houben-Weyl vol 10/4) in methylene chloride (250 ml) was added dropwise over I hour, maintaining the temperature at --40 -- -30"C. The mixture was then allowed to warm to -10"C. After 1 hour at -10"C the solution was washed with 3 portions of dilute sodiurn bicarbonate solution (200 ml), dried over calcium chloride and evaporated to give a brown gum. The product was purified by column chromatography (Kieselgel; cyclohexane:ethyl acetate 3:1 followed by 1:1) to give a slightly impure product. Repeat of the chromatography (same system) gave the desired product (ell) (1.56 g).
I.r. (film): 1805, 1750, 1698 cm-1.
N.m.r. (CDCl3): a 3.02(1H, doublet, J 17Hz), 3.45 (1H, double doublet, J 17Hz and 3Hz), 4.01 (2H, singlet), 4.14 (2H, doublet, J 7Hz), 4.70 (IH, triplet with fine coupling, Jtrip 7Hz), 5.06 (1H, singlet), 5.14 (2H, singlet), 5.66 (1H, singlet with fine coupling), 3.28 (5H, singlet).
Example 12 Preparation of Sodium 9-O-(cyanomethyl)clavulanate
A mixture of benzyl 9-(O-cyanomethyl)clavulanate (el 1) (1.56 g) and sodium bicarbonate (0.399 g) in tetrahydrofuran/water (30 ml 5:1 tetrahydrofuran:water) was hydrogenated over 10% palladium charcoal (0.5 g) at room temperature and atmospheric pressure, until the requisite amount of hydrogen had been absorbed.
The mixture was then filtered and the catalyst washed with water. The combined filtrates were then evaporated until most of the tetrahydrofuran had been removed.
The remaining aqueous solution was washed with ethyl acetate and freeze-dried to yield the desired product (e12) (913 mg) as a brown solid. A sample (535 mg) was passed through a short column of Kieselgel using n-butanol:H2O:EtOH (4:1:1) solvent to yield (e12) (213 mg) as a pale yellow solid.
N.m.r. (D2O): a 3.24 (liy, doublet, J 16Hz), 3.66 (1H, double doublet, J 16Hz and 3Hz), 4.30 (2H, doublet, J 7Hz), 4.40 (2H, singlet), 4.91 (1H, triplet with fine coupling, J 7Hz), 5.00 (1H, singlet), 5.78 (liy, doublet, 3Hz).
I.r. (KBr disc): 1780, 1610 (broad) cm-'.
Example 13 Preparation of Benzyl 9-O-(4-nitrobenzyl)clavulanate
A solution of benzyl clavulanate (el) (4.33 g) in methylene chloride (50 ml) was dried over 4A molecular sieves for + hour. The solution was then filtered and cooled to --300C. Boron trifluoride etherate (0.8 ml) was then added. A solution of 4-nitrophenyl diazomethane (7.34 g) in methylene chloride (150 ml) was then added to the stirred solution at -300C, over 1 hour. The mixture was then warmed to -10 C over a period of 1 hour. The solution was then washed with sodium bicarbonate solution (3xl50 ml), dried over magnesium sulphate and evaporated.
Repeated chromatography (twice with cyclohexane:ethyl acetate 1:1, and once with methylene chloride as eluant) on Kieselgel H gave the pure ether (e13) (230 mg).
I.r. (film): 1800, 1750, 1700, 1520 cm-'.
N.m.r. (CDCl3): 2.98 (liy, doublet, J 17Hz), 3.44 (liy, double doublet, J 17Hz and 3Hz), 4.09 (2H, doublet, J 7Hz), 3.45 (2H, singlet), 4.8 (lH, triplet with fine coupling, J 7Hz), 5.05 (1H, singlet), 5.14 (2H, singlet), 5.63 (1H, doublet with fine coupling), 7.27 (5H, singlet), 7.38 (2H, doublet, J 9Hz), 8.11 (2H, doublet, J 9Hz).
Example 14 Preparation of Benzyl 9-O-allylclavulanate
(i) N-Nitroso-N-allylbenzamide A solution of nitrogen dioxide (24.1 g) in carbon tetrachloride (150 ml) was again to a stirred mixture of anhydrous sodium acetate (45 g) and carbon tetrachoride (150 ml) at -200C. N-allylbenzamide (28.4 g) in carbon tetrachloride (150 ml) was added to the stirred mixture at -5 C which was then stirred at 0 C for 0.5 hour. This was washed with aqueous sodium bicarbonate (2x400 ml), dried, and evaporated to give N-nitroso-N-allylbenzamide (28.5 g).
imax (liquid film): 1710, 1650, 1600, 1570, 1355, 1285, 1155, 1040 and 920 cm-'.
S (CDCl3): 7.83-7.20 (5H, m, Arty, 6.03-4.83 (3H, m, # H), and 4.33 (2H, broad, d, J 4Hz).
(ii) 3-Diazoprop-l-ene Pyrrolidine (4.53 ml) was added to a solution of N-nitroso-N-allylbenzamide (9.5 g) in methylene chloride (100 ml) at -200C and the mixture was stirred at -200C for 15 minutes to give a solution of 3-diazoprop-1-ene.
Vmax (CH2CI2): 2030 cm-'. This solution was then stored at 0 C until use.
(iii) Benzyl 9-(O)-allylolavulanate Boron trifluoride etherate (1 ml) was added to a solution of benzyl clavulanate (2.89 g) in methylene chloride (150 ml) at -300C. The solution of 3-diazoprop-l-ene prepared above was added to the mixture at -300C and the solution was stirred at -300C to -10 C for hour. This was washed with aqueous sodium bicarbonate (2x200 ml), dried and evaporated to give the crude product as an oil which was chromatographed over silica gel (50 g). Elution of the column with cyclohexaneethyl acetate gave benzyl 9-(O)-allylclavulanate (e14) (0.92 g) as a colourless liquid, [erlD+45.3 (CHCl3; c, 1.0), vmax (liquid film): 1800, 1750, 1695, 1300, 1175, 1030, 1010, 995 cm-'.
S (CDCl3): 7.37 (SH, s, Ar-H), 6.05-5.70
5.60 (1H, d, J 2.5Hz, 5-CH), 5.30-5.10
5.13 (2H, s, -CH2Ph), 5.03 (1H, m, 3-CH), 4.79 (1H, broad t, J 8Hz, 8 CH), 4.01 (2H, d, J 8Hz, 9-CH2), 3.86 (2H, broad d, J 7Hz, -CH2- CH=CH3), 3.41 (1H, dd, J 18Hz, J' 2.5Hz, 6a-CH), 2.98 (1H', d, J 18Hz, 6B-CH).
(Found: C, 65.85; H, 5.65; N, 4.45%. C,8H19NO5 requires C, 65.65; H, 5.8; N, 4.25%).
Example 15 Preparation of Benzyl 9-O-(2-benzyloxycarbonylethyl)clavulanate
(i) Benzyl N-nitroso-N-benzyloxycarbonyl- -alanate A solution of nitrogen dioxide (6.9 g) in carbon tetrachloride (40 ml) was added to a stirred solution of anhydrous sodium acetate (12.3 g) and carbon tetrachloride (40 ml) at -200C. Benzyl N-benzyloxycarbonyl-fi-alanate (12.95 g) in carbon tetrachloride (50 ml) was added the stirred mixture at -50C which was then stirred at 0 C for 0.5 hour. The reaction mixture was washed with aqueous sodium bicarbonate (2x 100 ml) and the carbon tetrachloride solution was dried and evaporated to give benzyl N-nitroso-N-benzyloxycarbonyl- -alanate (12.5 g) as an oil, Vmax (CCl4): 1745, 1705, 1520, 1400, 1350, 1175, 1140, 1095, 960 cm-1, a (CDC1,): 7.30 (10H, s, ArH), 5.46 (2H, s, CH2Ph), 4.90 (2H, s, CH2Ph), 3.92 (2H, t, J 7Hz), and 2.36 (2H, t, J 7Hz).
(The n.m.r. spectrum indicated that the starting material and this oil were only about 73% pure).
(ii) Benzyl 9-O-(2-benzyloxycarbonylethyl)clavulanate Pyrrolidine (0.58 ml) was added to a solution of benzyl N-nitroso-Nbenzyloxycarbonyl-p-alanate (3.24 g) in methylene chloride (25 ml) at 200C and the mixture was stirred at -200C for 15 minutes to give a solution of benzyl 3diazopropionate which was kept at 0 C for the next stage.
Boron trifluoride etherate (0.5 ml) was added to a solution of benzyl clavulanate (1 g) in methylene chloride (150 ml) at-300C. The solution of benzyl 3diazopropionate prepared above was added to the mixture at -300C and the solution was stirred at -300C to -10"C for 1 hour. This was washed with aqueous sodium bicarbonate (2x50 ml), dried and evaporated to give the crude product as an oil which was chromatographed over silica gel (30 g). Elution of the column with cyclohexane - ethyl acetate gave benzyl 9 - 1O - (2 - benzyloxycarbonylethyl)] clavulanate (el5) (0.21 g) as a colourless liquid, lair 29.30 (CHCl3: c, 1.0), Vmax (liquid film): 1805 174, 1700, 1240, 1170, 1100, 1040 and 1020 cm-', (CDCl3): 7.28 (10H, s, Ar-H), 5.60 (1H, d, J 2.5Hz, 5-CH), 5.14 (2H, s, CH2Ph), 5.09 (2H, s, CH2Ph), 5.02(1 H, m, 3-CH), 4.74(1 H, broad t, J 8Hz, 8-CH), 4.01 (2H, broad d, J8Hz,9-CH2), 3.60(2H,t,J7Hz), 3.41 (1H, dd, J 18Hz, J' 2.5Hz, 6a-CH), 2.99 (lH, d, J 18Hz, 6,ii-CH) and 2.57 (2H, t, J 7Hz).
M+ 451.1626, C2sH25NO7 requires M+ 451.1631.
Example 16 Preparation of Disodium 9-0-(2-carboxyethyl)clavulanate
A mixture of benzyl 9-[O-(2-benzyloxycarbonylethyl)]clavulanate (e15) (0.17 g) and sodium bicarbonate (0.063 g) in tetrahydrofuran/water 5:1, 12 ml) was hydrogenated in the presence of 10% palladium charcoal (0.1 g) at room temperature and pressure for 0.5 hour. The mixture was filtered and the filtrate evaporated to give disodium 9-[O-(2-carboxyethyl)]clavulanate (e16) (0.084 g).
VmaX (KBr): 1780, 1690, 1620, 1390, 1310, 1195, 1155, 1085, 1040 and 895 cm-'.
a (D2O): 5.65 (1H, d, J 2.5Hz, 5-CH), 4.87 (1H, s, 3-CH), 4.81 (1H, broad t, J 8Hz, 8-CH), 4.06 (2H, d, J 8Hz, 9-CH2), 3.63 (3H, t, J 7Hz), 3.51(1 H, dd, J 18Hz, J' 2.5Hz, 6a-CH), 3.05 (1H, d, J 18Hz, 6,3-CH), and 2.49 (3H, t, J 7Hz).
Example 17 Preparation of B enzyl 9-O-acetonylclavulan ate
To a solution of benzyl clavulanate (el) (1.0 g) and diazoacetone (1.4 g) in methylene chloride (30 ml) was added boron trifluoride diethyletherate (20 drops).
and the solution stirred at -10 C for 2.0 hours. The reaction mixture was quenched with dilute bicarbonate solution. The organic extract was washed with sodium chloride solution, dried over magnesium sulphate and evaporated. Silica gel chromatography (eluting with ethyl acetate/cyclohexane) yielded the title product (e17) (190 mg) as a colourless oil.
I.r. (CHCl3): 1800, 17301760, 1695 cm-'; N.m.r. (CDCl3): 2.10 (3H, s, -CH3), 2.96 (IH, d, J 17Hz, 6 -CH), 3.36(1H, dd, J 17Hz, J' 2.5Hz, 6a-CH), 3.99 (2H, d, J 7Hz, =CH-CH2), 4.68 (1H, t, J 7Hz, =CH-CH2), 5.03 (1H, brs, 3-CH), 5.20 (2H, s, -CH2Ph),5.70(1H, d, J 2.5Hz, 5-CH), 7.33 (5H, s, CO2CH2Ph).
M (mass spectrometry) 345.
Example 18 Preparation of Sodium 9-O-acetonylclavulanate
The acetonyl ether benzyl ester (e17) (80 mg) was hydrogenated in a tetrahydrofuran/water mixture (5:1) in the presence of sodium bicarbonate (5 mg) and 10o, palladium/charcoal (30 mg.). After twenty minutes the catalyst was filtered off. The filtrate was diluted with water and extracted with ethyl acetate before freeze-drying. This yielded the title product as an off-white solid.
I.r. (KBr): 1780, 1720, 1690, 1610 cm-'; N.m.r. (CDCl3): 2.09 (3H, s, -CH3), 3.00 (IH, d, J 17Hz, 6 -CH), 3.45 (lH, dd, J 17Hz, J' 2.5Hz, 6a-CH), 4.08 (2H, d, J 8Hz, =CH-CH2), 4.18
4.80 (lH, t, J 8Hz, =CH), 4.90 (lH, s, 3-CH), 5.65 (lH, d, J 2.5Hz, 5-CH).
Example 19 Preparation of Benzyl 9-O-(4-chlorophenacyl) clavulanate
Benzyl clavulanate (el) (500 mg) was dissolved in methylene chloride (25 ml) and treated with -diazo-p-chloroacetophenone (0.90 g). To the stirring solution at -20 C was added boron trifluoride etherate (0.1 ml). The solution was stirred at -20 C to --100C for 2.0 hours, washed with dilute sodium bicarbonate solution (x2), and the organic extract dried over magnesium sulphate. Evaporation of the solvent and silica gel chromatography (eluting with chloroform) yielded the title compound (e19) (130 mg).
I.r. (CHCl3): 1805, 1750, 1695 cm-'; N.m.r. (CDCl3): 3.10 (lH, d, J 17Hz, 6pCH), 3.60 (liy, dd, J 17Hz, J' 2.5Hz, 6a- CH), 4.36 (2H, s, J 7Hz, =CH-CH2O-), 4.74
5.00 (IH, t, J, 7Hz, =CH-CH2), 5.26 (IH, brs, 3-CH), 5.37 (2H, s, CO2CH2Ph), 5.82 (IH, d, J 2.5Hz, 5-CH), 7.48-8.12 (9H, m, Aryl).
Example 20 Preparation of Benzyl 9-O-[2-(N-benzyloxycarbonyl-N methylamino)ethyljclavulanate
(i) N-Methy-N'-nitroso-N,N'-dibenzyloxycarbonyl- 1,2-diaminoethane To carbon tetrachloride (90 ml), stirred between -5" and 10 C, was added anhydrous sodium acetate (27.8 gm), followed by a solution of nitrogen dioxide (15.6 gm) in carbon tetrachloride (90 ml) at such a rate that the temperature did not rise above -5"C. A solution of N-methyl-N,N'-dibenzyloxycarbonyl-1,2- diaminoethane (29 gm) in carbon tetrachloride (90 1) was then added to the stirred solution over 40 minutes, maintaining the temperature at --100C. When the addition was complete the mixture was stirred for 2 hours. The mixture was then washed with excess sodium bicarbonate solution, the aqueous phase was extracted with carbon tetrachloride and the combined organic phases were dried over magnesium sulphate and evaporated to yield 29.8 g of approximately 80 , pure material.
(ii) N-Methyl-N,N'-dibenzyloxycarbonyl- 1,2-diaminoethane To a stirred solution of N-methyl-l,2-diaminoethane (7.4 gm) and triethylamine (20.2 gm) in chloroform (50 ml) at 0 C was added dropwise over 30 minutes benzyl chloroformate (34.1 gm). The mixture was then left to warm to room temperature over one hour. The organic solution was then washed with water, citric acid solution, sodium bicarbonate solution and finally water again.
The chloroform solution was dried over magnesium sulphate and evaporated to give a yellow oil (29.6 g).
(iii) Benzyl 9-l2-Benzyloxycarbonyl-N-Methylamino)etbyll clavulanate A stirred solution of N-methyl-N'-nitroso-N,N'-dibenzyloxycarbonyl- 1,2diaminoethane (3.71 gm) in methylene chloride (10 ml) was cooled to -300C and treated with pyrrolidine (0.71 gm). The mixture was stirred at 250 to 300C for half an hour and then used as described below.
A solution of benzyl clavulanate (1.0 gm) in methylene chloride (10 ml) was cooled to -30"C and treated with boron trifluoride etherate (0.5 ml). The solution of the diazo compound, prepared as described above, was then added to the stirred solution at such a rate as to keep the temperature below -25"C. The mixture was then stirred for one hour, gradually raising the temperature to -10"C. Excess icecold sodium bicarbonate solution was then added and the organic phase separated.
The aqueous phase was extracted with methylene chloride and the combined organic phases were washed with water, dried over magnesium sulphate and evaporated. Repeated chromatography of the residue gave the desired ether (e20).
I.r. (film), [No OH absortion], 1800, 1745 and 1700 cm-'.
Thin layer chromatographic properties consistent with formula.
Example 21 Preparation of Sodium 9-O-(4-nitrobenzyl)clavulanate
A solution of benzyl 9-[O-(4-nitrobenzyl)] clavulanate (e13) (110 mgs) and sodium bicarbonate (21.7 mgs) in tetrahydrofuran-water (5:1, 8 mls) was hydrogenated over 10% palladium on charcoal (68 mgs) for 15 minutes. The solution was filtered through Celite, and the solid was washed with water. The combined filtrates were evaporated to remove most of the tetrahydrofuran, and the remaining aqueous solution was washed with ethyl acetate. The aqueous solution was then evaporated and the residual gum was purified by column chromatography (Kieselgel H, n-butanol:water:ethanol, 4:1:1 as eluant) to give the product (e21) (39 mgs) as a yellow solid (estimated 70 " pure).
I.r. (KBr) 1790, 1605 (broad) cm-1.
N.m.r. (DMSO) 2.83 (IH, doublet, J 17Hz) 3.41 (IH, double doublet, J 17Hz and 3Hz) 3.88 (2H, doublet, J 7Hz), 4.4 (2H, singlet), 4.52 (IH singlet), 4.67 (IH, multiplet), 5.57 (IH, singlet with fine coupling), 6.46 (2H doublet J 9Hz), 6.89 (2H, doublet, J 9Hz).
Example 22 Preparation of Benzyl 9-O-(3-hydroxypropyl)clavulanate
(i) N,O-bis-(benzyloxycarbonyl)-3-aminopropanol Benzyl chloroformate (47 ml.) was added dropwise to a stirred solution of 3aminopropanol (11.4 ml) in pyridine (150 ml) at 0 C. The mixture was then stirred at room temperature overnight. This was poured into ice-water (300 ml) and extracted with ethyl acetate (3x200 ml). The organic extract was washed with hydrochloric acid (5m, 3x400 ml), dried with anhydrous sodium carbonate magnesium sulphate and evaporated to give the desired compound as an oil contaminated with a little dimethyl carbonate (30.23 g).
(ii) Nitroso-N,O- bis-(benzyloxycarbonyl)-3-Aminopropanol Anhydrous sodium acetate (45 g) was added to carbon tetrachloride (150 ml) at 0 C and the mixture was cooled to -20"C and then added to a solution of nitrogen dioxide (24.1 g) in carbon tetrachloride (150 ml). A solution of N,O-bis (benzoyloxyvarbonyl)-3-aminopropanol (30.23 g) in carbon tetrachloride (150 ml) was added to the stirred mixture at -50C which was then stirred at 0 C for half and hour. The reaction mixture was washed with aqueous sodium bicarbonate (2x400 ml), dried, and evaporated to give the desired compound as an oil (31.23 g), /'max (liquid film) 1750, 1510, 1400, 1260, 1125 and 1035.
(iii) Benzyl 9-O-(3-benzyloxycarbonyloxypropyl)clavulanate Pyrrolidine (4.94 ml) was added to a solution of N-nitroso-N,O-bis (benzyloxycarbonyl)-3-aminopropanol (31.22 g) 0.056 mole in the mixture) in methylene chloride (100 ml) at -200C for 15 minutes to give a solution of 3-diazo O-benzyloxycarbonyl-propanol, Vmax (CH2CI2) 2030 cm-'. This solution was kept at OOC for the next stage.
Boron trifluoride etherate (1 ml) was added to a solution of benzyl clavulanate (3 g) in methylene chloride (150 ml) at -300C. The solution of 3-diazo-Obenzyloxycarbonylpropanol prepared above was added to the mixture at -300C and the solution was stirred at -30 to -100C for 1 hour. This was washed with aqueous sodium bicarbonate (2x200 ml), dried, and evaporated to give an oil which was chromatographed using silica gel (80 g). Elution of the column with cyclohexaneethyl acetate afforded the title compound (e22) (1.5 g), b (CDCl3) 7.36 (10H, s, ArH), 5.70 (IH, d, J=2.5Hz, 5-CH), 5.18 (4H, s, CH2Ph), 5.13 (IH, m, 3 CH), 4.84 (IH, broad t, J=8Hz, 8-CH), 4.26 (IH, 5, J=6Hz, CH2 CH2 OCBz), 4.06 (IH, d, J=8Hz, 9-CH2), 3.603.26 (4H, m, O-CH3CH2 and 6a-CH), 3.02, (IH, d, J=18Hz, 6p-CH), and 1.86 (IH, m, CH2CH2CH2).
Example 23 Preparation of Sodium 9-O-(3-hydroxypropyl)clavulanate
A mixture of benzyl 9-O-(3-benzyloxycarbonyloxypropyl)clavulanate (0.5 g) and sodium bicarbonate (0.05 g) in tetrahydrofuran-water (S=l, 12 ml) was hydrogenated at room temperature and pressure in the presence of 10% palladiumcharcoal (0.3 g) for 15 minutes. The mixture was filtered and the filtrate evaporated to give an oil which was partitioned between water and ethyl acetate. The aqueous fraction was freeze-dried to give the title compound (e23) with a consistent n.m.r.
spectrum.
Example 24 Biological Activity a. When administered to mice the compounds of this invention do not exhibit a high level of toxicity, for example on sub-cutaneous administration the compounds of Examples 5 and 12 have LD50 values of greater than 250 mg/kg.
b. When tested in standard MIC tests in combination with ampicillin the compounds of this invention are seen to enhance the effectiveness of the penicillin against various gram-positive and gram-negative organisms such as strains of Staphvlococcus aureus Russell, Klebsiella aerogenes, Proteus mirabilis and Escherichia coli: for example the following MIC values against Staphylococcus aureus Russell were obtained for ampicillin in the presence of 1 ,ug/ml of certain compounds of the invention: Compound of Example No: 3 5 9 10 11 14 15 16 MIC (ig/ml): 2 0.3 1.6 3 1.25 1.25 1 1 Ampicillin in the absence of synergist did not inhibit the growth of the test organism at a concentration of 250 ,ig/ml. None of the synergists inhibited the growth of the test organism at 5 ,ug/ml.
WHAT WE CLAIM IS: 1. A compound of the formula (ill):
or a salt or ester thereof wherein R is an inert etherifying organic group of up to 18 carbon atoms.
2. A compound as claimed in claim 1 of the formula (III):
or a salt or ester thereof wherein CH2R' is an inert etherifying organic group of up to 18 carbon atoms.
3. A compound as claimed in claim 1 or 2 wherein the inert etherifying group is a hydrocarbon group.
4. A compound as claimed in any of claims 1, 2 or 3 wherein the etherifying group is an alkyl group.
5. A compound as claimed in any of claims 1, 2 or 3 wherein the etherifying group is an alkyl group substituted by a phenyl group.
6. A compound as claimed in any of claims 1, 2 or 3 wherein the etherifying group is an alkenyl group.
7. A compound as claimed in any of claims 1, 2 or 3 wherein the inert etherifying group is a hydrocarbon group substituted by a halogen atom.
8. A compound as claimed in claims 1 or 2 wherein the inert etherifying group is a hydrocarbon group substituted by a group OR2 wherein R2 is a hydrocarbon group of up to 8 carbon atoms.
9. A compound as claimed in claims 1 or 2 wherein the inert etherifying group is a hydrocarbon group substituted by a hydroxyl group.
**WARNING** end of DESC field may overlap start of CLMS **.

Claims (217)

  1. **WARNING** start of CLMS field may overlap end of DESC **.
    hydrogenated at room temperature and pressure in the presence of 10% palladiumcharcoal (0.3 g) for 15 minutes. The mixture was filtered and the filtrate evaporated to give an oil which was partitioned between water and ethyl acetate. The aqueous fraction was freeze-dried to give the title compound (e23) with a consistent n.m.r.
    spectrum.
    Example 24 Biological Activity a. When administered to mice the compounds of this invention do not exhibit a high level of toxicity, for example on sub-cutaneous administration the compounds of Examples 5 and 12 have LD50 values of greater than 250 mg/kg.
    b. When tested in standard MIC tests in combination with ampicillin the compounds of this invention are seen to enhance the effectiveness of the penicillin against various gram-positive and gram-negative organisms such as strains of Staphvlococcus aureus Russell, Klebsiella aerogenes, Proteus mirabilis and Escherichia coli: for example the following MIC values against Staphylococcus aureus Russell were obtained for ampicillin in the presence of 1 ,ug/ml of certain compounds of the invention: Compound of Example No:
    3 5 9 10 11 14 15 16 MIC (ig/ml): 2 0.3 1.6 3 1.25 1.25 1 1 Ampicillin in the absence of synergist did not inhibit the growth of the test organism at a concentration of 250 ,ig/ml. None of the synergists inhibited the growth of the test organism at 5 ,ug/ml.
    WHAT WE CLAIM IS: 1. A compound of the formula (ill):
    or a salt or ester thereof wherein R is an inert etherifying organic group of up to 18 carbon atoms.
  2. 2. A compound as claimed in claim 1 of the formula (III):
    or a salt or ester thereof wherein CH2R' is an inert etherifying organic group of up to 18 carbon atoms.
  3. 3. A compound as claimed in claim 1 or 2 wherein the inert etherifying group is a hydrocarbon group.
  4. 4. A compound as claimed in any of claims 1, 2 or 3 wherein the etherifying group is an alkyl group.
  5. 5. A compound as claimed in any of claims 1, 2 or 3 wherein the etherifying group is an alkyl group substituted by a phenyl group.
  6. 6. A compound as claimed in any of claims 1, 2 or 3 wherein the etherifying group is an alkenyl group.
  7. 7. A compound as claimed in any of claims 1, 2 or 3 wherein the inert etherifying group is a hydrocarbon group substituted by a halogen atom.
  8. 8. A compound as claimed in claims 1 or 2 wherein the inert etherifying group is a hydrocarbon group substituted by a group OR2 wherein R2 is a hydrocarbon group of up to 8 carbon atoms.
  9. 9. A compound as claimed in claims 1 or 2 wherein the inert etherifying group is a hydrocarbon group substituted by a hydroxyl group.
  10. 10. A compound as claimed in claims 1 or 2 wherein the inert etherifying group
    is a hydrocarbon group substituted by a O . CO . R2 group where R2 is a hydrocarbon group of up to 8 carbon atoms.
  11. 11. A compound as claimed in claims 1 or 2 wherein the inert etherifying group is a hydrocarbon group substituted by a CO2R2 group where R2 is a hydrocarbon group of up to 8 carbon atoms.
  12. 12. A compound as claimed in claims 1 or 2 wherein the inert etherifying group is a hydrocarbon group substituted by a NR3COR2 group where R2 is a hydrocarbon group of up to 8 carbon atoms and R3 is a hydrocarbon group of up to 4 carbon atoms.
  13. 13. A compound as claimed in claims 1 or 2 wherein the inert etherifying group is a hydrocarbon group substituted by a SO. R2 group wherein R2 is a hydrocarbon group of up to 8 carbon atoms.
  14. 14. A compound as claimed in claims 1 or 2 wherein the inert etherifying group is a hydrocarbon group substituted by a SO2R2 group wherein R2 is a hydrocarbon group of up to 8 carbon atoms.
  15. 15. A compound as claimed in claims 1 or 2 wherein the inert etherifying group is a hydrocarbon group substituted by a NH2 group.
  16. 16. A compound as claimed in claims I or 2 wherein the inert etherifying group is a hydrocarbon group substituted by a NR2R3 group wherein R2 is a hydrocarbon group of up to 8 carbon atoms and R3 is a hydrocarbon group of up to 4 carbon atoms.
  17. 17. A compound as claimed in claims 1 or 2 wherein the inert etherifying group is a hydrocarbon group substituted by a NO2 group.
  18. 18. A compound as claimed in claims 1 or 2 wherein the inert etherifying group is a hydrocarbon group substituted by a CN group.
  19. 19. A compound as claimed in claims 1 or 2 wherein the inert etherifying group is a hydrocarbon group substituted by a CO . NR2R3 wherein R2 is a hydrocarbon group of up to 8 carbon atoms and R3 is a hydrocarbon group of up to 4 carbon atoms.
  20. 20. A compound as claimed in any of claims 9, 10, 11, 12, 13, 14, 16 or 17 wherein R2 is a methyl, ethyl, propyl, butyl, phenyl or benzyl group.
  21. 21. A compound as claimed in any of claims 10, 11, 12, 13, 14, 16, or 17 wherein R2 is a methyl group.
  22. 22. A compound as claimed in any of claims 4, 10, 11, 12, 13, 14, 16, 19 or 21 wherein R3 is a methyl group.
  23. 23. A compound as claimed in claim 1 wherein the inert etherifying organic group is a methyl group.
  24. 24. A compound as claimed in claim 2 wherein R1 is a methyl group.
  25. 25. A compound as claimed in claim 2 wherein R' is an ethyl group.
  26. 26. A compound as claimed in claim 2 wherein R' is a propyl group.
  27. 27. A compound as claimed in claim 2 wherein R' is a butyl group.
  28. 28. A compound as claimed in claim 2 wherein R' is a phenyl group.
  29. 29. A compound as claimed in claim 2 wherein R' is a naphthyl group.
  30. 30. A compound as claimed in claim 2 wherein R' is a phenyl group substituted bp a halogen or a group OR4 or R4 wherein R4 is a methyl, ethyl or propyl group.
  31. 31. A compound as claimed in claims 1 or 2 wherein the etherifying group is of the sub-formula (a): -CH2-X-CO2H (a) wherein X is a bond or CH2 group.
  32. 32. A compound as claimed in claims I or 2 wherein the etherifying group is of the sub-formula (b): -CH2-X-CO2R5 (b) wherein X is a bond or CH2 group and R5 is a methyl, ethyl, propyl or butyl group or is a methyl, ethyl, propyl or butyl group substituted by a phenyl group.
  33. 33. A compound as claimed in claims 1 or 2 wherein the etherifying group is of the sub-formula (c): -CH2-Y-NR6R7 (c) wherein -CH2-Y is an alkylene group of 2 to 4 carbon atoms or an alkylene group of 2 to 4 carbon atoms substituted by a phenyl group; R6 is a hydrogen atom or a methyl, ethyl, propyl or butyl group; and R7 is a hydrogen atom or a group R8, CO. R8 or COPRA wherein R8 is a methyl, ethyl, propyl or butyl group substituted by a phenyl group.
  34. 34. A compound as claimed in claim 33 wherein Y is a CH2 group.
  35. 35. A compound as claimed in claims 33 or 34 wherein R6 is a methyl group.
  36. 36. A compound as claimed in any of claims 33, 34 or 35 wherein R7 is a benzyloxycarbonyl group.
  37. 37. A compound as claimed in any of claims 33, 34 or 35 wherein R7 is a hydrogen atom.
  38. 38. A compound as claimed in claim I wherein the etherifying group is the ethoxycarbonylmethyl group.
  39. 39. A compound as claimed in claim 1 wherein the etherifying group is the benzoyloxycarbonylmethyl group.
  40. 40. A compound as claimed in claim 1 wherein the etherifying group is the carboxymethyl group.
  41. 41. A compound as claimed in claim 1 wherein the etherifying group is the cyanomethyl group.
  42. 42. A compound as claimed in claim 1 wherein the etherifying group is the pnitrobenzyl group.
  43. 43. A compound as claimed in claim 1 wherein the etherifying group is the allyl group.
  44. 44. A compound as claimed in claim I wherein the etherifying group is the 2benzyloxycarbonylethyl group.
  45. 45. A compound as claimed in claim 1 wherein the etherifying group is the 7- carboxyethyl group.
  46. 46. A compound as claimed in claim 1 wherein the etherifying group is the acetonyl group.
  47. 47. A compound as claimed in claim 1 wherein the etherifying group is the 4chlorophenacyl group.
  48. 48. A compound as claimed in claim 1 wherein the etherifying group is the 3hydroxypropyl group.
  49. 49. A compound as claimed in claim I wherein the etherifying group is the 2 (N-benzyloxycarbonyl-N-methylamino)ethyl group.
  50. 50. A compound as claimed in claim 1 in the form of the acid or a pharmaceutically acceptable salt thereof.
  51. 51. A compound as claimed in claim 50 which is a sodium salt.
  52. 52. A compound as claimed in claim 50 which is a potassium salt.
  53. 53. A compound as claimed in claim 50 which is a calcium salt.
  54. 54. A compound as claimed in claim 50 which is a magnesium salt.
  55. 55. A compound as claimed in any of claims 2, 3 or 4 in the form of the acid or a pharmaceutically acceptable salt thereof.
  56. 56. A compound as claimed in claim 55 which is a sodium salt.
  57. 57. A compound as claimed in claim 55 which is a potassium salt.
  58. 58. A compound as claimed in claim 55 which is a calcium salt.
  59. 59. A compound as claimed in claim 55 which is a magnesium salt.
  60. 60. A compound as claimed in any of claims 24 to 28 in the form of the acid or a pharmaceutically acceptable salt thereof.
  61. 61. A compound as claimed in claim 60 which is a sodium salt.
  62. 62. A compound as claimed in claim 60 which is a potassium salt.
  63. 63. A compound as claimed in claim 60 which is a calcium salt.
  64. 64. A compound as claimed in any of claims 8 to 22 or 29 to 49 in the form of the acid or a pharmaceutically acceptable salt thereof.
  65. 65. A compound as claimed in claim 64 which is a sodium salt.
  66. 66. A compound as claimed in claim 64 which is a potassium salt.
  67. 67. A compound as claimed in claim 64 which is a calcium salt.
  68. 68. A compound as claimed in claim 64 which is a magnesium salt.
  69. 69. A compound as claimed in claim 1 which is an ester of the compound of the formula (II).
  70. 70. A compound as claimed in claim 69 of the formula (IV):
    wherein R is as defined in claim I and A' is an alkyl group of 1 to 8 carbon atoms optionally substituted by a halogen or a group of the formula OA4, OCOA4, SA4 or SO2A4 wherein A4 is a hydrocarbon group of up to 6 carbon atoms.
  71. 71. A compound as claimed in claim 70 wherein A' is methyl.
  72. 72. A compound as claimed in claim 69 of the formula (V):
    wherein R is as defined in claim 1 and A2 is a hydrogen atom or an alkyl group of up to 4 carbon atoms or a phenyl group optionally substituted by a halogen or a group A5 or OA5 where A5 is an alkyl group of up to 6 carbon atoms, and A3 is a phenyl group optionally substituted by halogen or by a group A5 or OA5 where A5 is an alkyl group of up to 6 carbon atoms.
  73. 73. A compound as claimed in claim 72 wherein A2 is a hydrogen atom.
  74. 74. A compound as claimed in claim 72 wherein CHA2A3 is a benzyl group.
  75. 75. A compound as claimed in claim 69 which is hydrolysable in vivo.
  76. 76. A compound as claimed in claim 69 which is a phthalidyl ester.
  77. 77. A compound as claimed in claim 69 which is an a-acetoxyethyl ester.
  78. 78. A compound as claimed in claim 69 which is an ethoxycarbonyloxymethyl ester.
  79. 79. A compound as claimed in claim 69 which is an a-ethoxycarbonyloxyethyl.
  80. 80. 9-O-Methylclavulanic acid or a pharmaceutically acceptable salt or ester thereof.
  81. 81. 9-O-Methylclavulanic acid or a pharmaceutically acceptable salt thereof.
  82. 82. Methyl 9-O-Methylclavulanate.
  83. 83. Benzyl 9-O-methylclavulanate.
  84. 84. Sodium 9-O-methylclavulanate.
  85. 85. Potassium 9-O-methylclavulanate.
  86. 86. Calcium 9-O-methylclavulanate.
  87. 87. Magnesium 9-O-methylclavulanate.
  88. 88. A compound as claimed in claim 1 in the form of a triethylamine salt.
  89. 89. A compound as claimed in claim 1 in the form of a trimethylamine salt.
  90. 90. A pharmaceutical composition which comprises a compound of the formula (II) as claimed in claim I or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable carrier therefor.
  91. 91. A composition as claimed in claim 90 wherein the compound as claimed in claim 1 is a compound as claimed in any of claims 50 to 54.
  92. 92. A composition as claimed in claim 90 wherein the compound as claimed in claim 1 is a compound as claimed in any of claims 55 to 59.
  93. 93. A composition as claimed in claim 90 wherein the compound as claimed in claim 1 is a compound as claimed in any of claims 60 to 63.
  94. 94. A composition as claimed in claim 90 wherein the compound as claimed in claim 1 is a compound as claimed in any of claims 64 to 68.
  95. 95. A composition as claimed in claim 90 wherein the compound as claimed in claim I is a compound as claimed in any of claims 75 to 79.
  96. 96. A pharmaceutical composition which comprises a compound as claimed in claim 80 and a pharmaceutically acceptable carrier.
  97. 97. A pharmaceutical composition which comprises a compound as claimed in claim 81 and a pharmaceutically acceptable carrier.
  98. 98. A pharmaceutical composition which comprises the compound claimed in claim 82 and a pharmaceutically acceptable carrier.
  99. 99. A pharmaceutical composition which comprises the compound claimed in claim 83 and a pharmaceutically acceptable carrier.
  100. 100. A pharmaceutical composition which comprises the compound claimed in claim 84 and a pharmaceutically acceptable carrier.
  101. 101. A pharmaceutical composition which comprises the compound claimed in claim 85 and a pharmaceutically acceptable carrier.
  102. 102. A pharmaceutical composition which comprises the compound claimed in claim 86 and a pharmaceutically acceptable carrier.
  103. 103. A pharmaceutical composition which comprises the compound claimed in claim 87 and a pharmaceutically acceptable carrier.
  104. 104. A composition as claimed in claim 90 which also comprises a penicillin or cephalosporin.
  105. 105. A composition as claimed in claim 91 which also comprises a penicillin or cephalosporin.
  106. 106. A composition as claimed in claim 92 which also comprises a penicillin or cephalosporin.
  107. 107. A composition as claimed in claim 93 which also comprises a penicillin or cephalosporin.
  108. 108. A composition as claimed in claim 94 which also comprises a penicillin or cephalosporin.
  109. 109. A composition as claimed in claim 95 which also comprises a penicillin or cephalosporin.
  110. 110. A composition as claimed in claim 96 which also comprises a penicillin or cephalosporin.
  111. 111. A composition as claimed in claim 97 which also comprises a penicillin or cephalosporin.
  112. 112. A composition as claimed in claim 98 which also comprises a penicillin or cephalosporin.
  113. 113. A composition as claimed in claim 99 which also comprises a penicillin or cephalosporin.
  114. 114. A composition as claimed in claim 100 which also comprises a penicillin or cephalosporin.
  115. 115. A composition as claimed in claim 101 which also comprises a penicillin or cephalosporin.
  116. 116. A composition as claimed in claim 102 which also comprises a penicillin or cephalosporin.
  117. 117. A composition as claimed in claim 103 which also comprises a penicillin or cephalosporin.
  118. 118. A composition as claimed in claim 104 which comprises benzylpenicillin, phenoxymethylpenicillin, propicillin, ampicillin, amoxycillin, epicillin, cyclacillin, hetacillin, metampicillin or the acetoxymethyl, pivaloyloxymethyl or phthalidyl esters of benzylpenicillin, ampicillin or amoxycillin or the phenyl, tolyi or indanyl ester of carbenicillin or ticarcillin.
  119. 119. A composition as claimed in claim 104 which comprises carbenicillin or ticarcillin.
  120. 120. A composition as claimed in claim 104 which comprises cephaloridine, cephalothin, cefazolin, cephalexin, cephacetrile, cephradine, cephapirin or cephaloglycine.
  121. 121. A composition as claimed in any of claims 105 to 107 which comprises a penicillin named in claim 118.
  122. 122. A composition as claimed in any of claims 105 to 107 which comprises a penicillin as named in claim 119.
  123. 123. A composition as claimed in any of claims 105 to 107 which comprises a cephalosporin as named in claim 120.
  124. 124. A composition as claimed in any of claims 108 to 110 which comprises a penicillin named in claim 118.
  125. 125. A composition as claimed in any of claims 108 to 110 which comprises a penicillin named in claim 119.
  126. 126. A composition as claimed in any of claims 108 to 110 which comprises a cephalosporin named in claim 120.
  127. 127. A composition as claimed in any of claims 111 to 117 which comprises a penicillin named in claim 118.
  128. 128. A composition as claimed in any of claims 111 to 117 which comprises a penicillin named in claim 119.
  129. 129. A composition as claimed in any of claims 111 to 117 which comprises a cephalosporin as claimed in claim 120.
  130. 130. A composition as claimed in any of claims 104, 118, 119 or 120 of this invention wherein the weight ratio of the compound of the formula (II) or its pharmaceutically acceptable salt or ester to penicillin or cephalosporin is 1:3 to 3:1.
  131. 131. A composition as claimed in any of claims 105 to 107 and 121 to 123 wherein the weight ratio of the compound of the formula (II) or its pharmaceutically acceptable salt to penicillin or cephalosporin is 1:3 to 3:1.
  132. 132. A composition as claimed in any of claims 108 and 109 and 124 to 126 wherein the weight ratio of compound of the formula (II) or its pharmaceutically acceptable salt or ester to penicillin or cephalosporin is 1:3 to 3:1.
  133. 133. A composition as claimed in any of claims 110 to 117 and 127 to 129 wherein the weight ratio of compound as claimed in claims 80 to 87 to penicillin or cephalosporin is 1:3 to 3:1.
  134. 134. A composition as claimed in claim 90 adapted for oral administration.
  135. 135. A composition as claimed in claim 80 adapted for administration by injection.
  136. 136. A composition as claimed in any of claims 118, 124, or 127 adapted for oral administration.
  137. 137. A composition as claimed in any of claims 119, 122 or 128 adapted for administration by injection.
  138. 138. A composition as claimed in any of claims 120, 123 or 129 adapted for administration by injection.
  139. 139. A composition as claimed in claim 135 which comprises a sterile salt of compound as claimed in claims 1 or 23.
  140. 140. A composition as claimed in any of claims 90, 96 to 104, 110 to 118 and 121 which is in the form of a tablet.
  141. 141. A composition as claimed in any of claims 90,96 to 104, 110 to 117, 119 or 120 in the form of an injectable composition.
  142. 142. A pharmaceutical composition which comprises from 150 to 1000 mg of amoxycillin or ampicillin or a pro-drug for amoxycillin or ampicillin. from 50 to 500 mg of a compound of the formula (II) as claimed in claim 1 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, and a pharmaceutically acceptable carrier.
  143. 143. A composition as claimed in claim 142 which comprises from 200 to 500 mg of amoxycillin or ampicillin or a pro-drug for amoxycillin or ampicillin.
  144. 144. A composition as claimed in claims 142 or 143 which comprises from 50 to 250 mg of a compound of the formula (II) as claimed in claim I or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof.
  145. 145. A composition as claimed in any of claims 142 to 144 which comprises amoxycillin.
  146. 146. A composition as claimed in any of claims 142 to 144 which comprises ampicillin.
  147. 147. A composition as claimed in any of claims 142 to 146 which comprises a compound as claimed in claims 80 or 81.
  148. 148. A composition as claimed in any of claims 142 to 146 which comprises the compound claimed in claim 82.
  149. 149. A composition as claimed in any of claims 142 to 146 which comprises a compound as claimed in any of claims 84 to 87.
  150. 150. A composition as claimed in any of claims 142 to 149 which comprises amoxycillin trihydrate.
  151. 151. A composition as claimed in any of claims 142 to 150 which comprises ampicillin trihydrate.
  152. 152. A composition as claimed in any of claims 142 to 148 adapted for oral administration.
  153. 153. A composition as claimed in any of claims 149 to 151 adapted for oral administration.
  154. 154. A composition as claimed in any of claims 142 to 150 adapted for administration by injection.
  155. 155. A composition as claimed in any of claims 142 to 149 in the form of a tablet or capsule.
  156. 156. A composition as claimed in claim 150 or 151 in the form of a tablet or capsule.
  157. 157. A process for the preparation of a composition as claimed in any of claims 104-156 which comprises bringing the components thereof together in known manner.
  158. 158. A composition prepared by the process of claim 157.
  159. 159. A process for the preparation of a compound of the formula (II) as claimed in claim 1 or a salt or ester thereof which process comprises the etherification of an ester of clavulanic acid and thereafter if desired cleaving a thus produced ester of the compound of the formula (II) by hydrogenolysis or hydrolysis to yield the compound of the formula (II) or its salt.
  160. 160. A process as claimed in claim 159 adapted for the preparation of a compound as claimed in claim 2 wherein the etherification is effected by reaction of an ester of clavulanic acid with a diazoalkane of the formula N2-CHR1 where Rl is as defined in claim 2.
  161. 161. A process as claimed in claim 159 adapted to the preparation of a compound as claimed in claim 23.
  162. 162. A process as claimed in any of claims 159-161 wherein the ester of clavulanic acid is the methyl or benzyl ester.
  163. 163. A process for the preparation of a salt of a compound as claimed in claim 1 which comprises the very mild basic hydrolysis of an ester of the compound as claimed in claim 1.
  164. 164. A process as claimed in claim 163 adapted to the preparation of a salt as claimed in any of claims 51 to 54 and 84 to 87.
  165. 165. A process for the preparation of a compound as claimed in claim 1 or a salt thereof which comprises the hydrogenation of a hydrogenolysable ester of the compound as claimed in claim 1 optionally in the presence of a base.
  166. 166. A process as claimed in claim 165 wherein the hydrogenolysable ester is the benzyl ester.
  167. 167. A process as claimed in claim 165 or 166 wherein the hydrogenation is effected in the presence of a 10 ' palladium on charcoal catalyst.
  168. 168. A process as claimed in claim 159 which process comprises the reaction of the corresponding ester of clavulanic acid with a compound of the formula RQ where R is as defined in claim 1 and Q is a group readily displaceable by an electron-rich moiety.
  169. 169. A process as claimed in claim 168 wherein Q is a chlorine, bromine or iodine atom.
  170. 170. A process as claimed in claim 169 adapted to the preparation of a compound as claimed in claim 2.
  171. 171. A compound as claimed in claim 1 when prepared by a process as claimed in claim 159.
  172. 172. A compound as claimed in claim 1 when prepared by a process as claimed in claim 161.
  173. 173. A compound as claimed in claim 1 when prepared by a process as claimed in claim 162.
  174. 174. A salt of a compound of the formula (II) as claimed in claim 1 when prepared by the process as claimed in claim 163.
  175. 175. A salt of a compound of the formula (II) as claimed in any of claims 51 to 54 and 84 to 87 when prepared by a process as claimed in claim 164.
  176. 176. A compound of the formula (II) or a salt thereof when prepared by a process as claimed in any of claims 165 to 167.
  177. 177. The compound of claim 82 when prepared by the methylation of methylclavulanate.
  178. 178. A compound as claimed in any of claims 84 to 87 when prepared by a process as claimed in claim 163.
  179. 179. A method of treating bacterial infection in mammals excluding humans which comprises administering thereto a composition as claimed in any of claims 90, 91 and 96 to 103.
  180. 180. A method of treating bacterial infection in mammals excluding humans which comprises administering thereto a composition as claimed in any of claims 104, 105, 110 to 120 or 130.
  181. 181. A method of treating bacterial infection in mammals excluding humans which comprises administering thereto a composition as claimed in any of claims 142 to 146.
  182. 182. A method of treating bacterial infection in mammals excluding humans which comprises administering thereto a composition as claimed in any of claims 147 to 149.
  183. 183. A method as claimed in any of claims 180 or 181 wherein the composition to be administered is as claimed in claims 150 or 151.
  184. 184. A method as claimed in claim 179 wherein the composition is administered orally or by injection.
  185. 185. A method as claimed in claim 180 wherein the composition is administered orally or by injection.
  186. 186. A method as claimed in claim 181 wherein the composition is administered orally or by injection.
  187. 187. A method as claimed in claim 182 wherein the composition is administered orally or by injection.
  188. 188. A method as claimed in claim 183 wherein the composition is administered orally or by injection.
  189. 189. A method as claimed in claims 179 or 184 wherein the infection is mastitis in cattle.
  190. 190. A method as claimed in claims 180 or 185 wherein the infection is mastitis in cattle.
  191. 191. A method as claimed in claims 181 or 186 wherein the infection is mastitis in cattle.
  192. 192. A method as claimed in claims 182 or 187 wherein the infection is mastitis in cattle.
  193. 193. A method as claimed in claims 183 or 188 wherein the infection is mastitis in cattle.
  194. 194. A process for the preparation of a compound of the formula (II) or a salt thereof as claimed in claim 1 which comprises the de-esterification of an ester of the compound of the formula (II).
  195. 195. Methyl 9-O-methylclavulanate substantially as described in Example 1.
  196. 196. Benzyl 9-O-methylclavulanate substantially as described in Example 2.
  197. 197. Sodium 9-O-methylclavulanate substantially as described in Example 3.
  198. 198. Methyl 9-O-benzylclavulanate substantially as described in Example 4.
  199. 199. Sodium 9-O-benzylclavulanate substantially as described in Example 5.
  200. 200. Benzyl 9-O-(ethoxycarbonylmethyl)clavulanate substantially as described in Example 6.
  201. 201. Sodium 9-O-(ethoxycarbonylmethyl)clavulanate substantially as described in Example 7.
  202. 202. Sodium 9-O-(ethoxycarbonylmethyl)clavulanate substantially as described in Example 8.
  203. 203. Benzyl 9-O-(benzyloxycarbonylmethyl)clavulanate substantially as described in Example 9.
  204. 204. Di-sodium 9-O-(carboxymethyl)clavulanate substantially as described in Example 10.
  205. 205. Benzyl 9-O-(cyanomethyl)clavulanate substantially as described in Example 11.
  206. 206. Sodium 9-O-(cyanomethyl)clavulanate substantially as described in Example 12.
  207. 207. Benzyl 9-O-(4-nitrobenzyl)clavulanate substantially as described in Example 13.
  208. 208. Benzyl 9-O-allylclavulanate substantially as described in Example 14.
  209. 209. Benzyl 9-O-(2-benzyloxycarbonylethyl)clavulanate substantially as described in Example 15.
  210. 210. Disodium 9-O-(2-carboxyethyl)clavulanate substantially as described in Example 16.
  211. 211. Benzyl 9-O-acetonylclavulanate substantially as described in Example 17.
  212. 212. Sodium 9-O-acetonylclavulanate substantially as described in Example 18.
  213. 213. Benzyl 9-0-(4-chlorophenacyl)clavulanate substantially as described in Example 19.
  214. 214. B enzyl 9-O-[2-(N-B enzyloxycarbonyl-N-methylamino)ethyll clavulanate substantially as described in Example 20.
  215. 215. Sodium 9-O-(4-nitrobenzyl)clavulanate substantially as described in Example 21.
  216. 216. Benzyl 9-O-(3-hydroxypropyl)clavulanate substantially as described in Example 22.
  217. 217. Sodium 9-0-(3-hydroxypropyl)clavulanate substantially as described in Example 23.
GB4189775A 1975-10-13 1975-10-13 Clavulanic acid derivatives Expired GB1565209A (en)

Priority Applications (50)

Application Number Priority Date Filing Date Title
GB4189775A GB1565209A (en) 1975-10-13 1975-10-13 Clavulanic acid derivatives
IE2047/76A IE44295B1 (en) 1975-10-13 1976-09-14 Clavulanic acid derivatives
ZA765560A ZA765560B (en) 1975-10-13 1976-09-16 Antibacterial agents
ZM11776A ZM11776A1 (en) 1975-10-13 1976-09-17 Antibacterial agents
IL50514A IL50514A (en) 1975-10-13 1976-09-20 Clavulanic acid ethers their preparation and pharmaceutical compositions containing them
AU18033/76A AU512859B2 (en) 1975-10-13 1976-09-22 Ethers of clavulanic acid
PT65622A PT65622B (en) 1975-10-13 1976-09-22 Antibacterial agents
PH18946A PH16904A (en) 1975-10-13 1976-09-27 Beta-lactam antibacterial agents
NZ182046A NZ182046A (en) 1975-10-13 1976-10-05 9-0-ethers of clavulanic acid,saltd and esters and pharmaceutical compositions
SE7611045A SE440080B (en) 1975-10-13 1976-10-05 PROCEDURE FOR THE PREPARATION OF CLAVULANIC ACID DERIVATIVES
BE171322A BE847045A (en) 1975-10-13 1976-10-07 CLAVULANIC ACID DERIVATIVES,
AT753376A AT352873B (en) 1975-10-13 1976-10-11 PROCESS FOR MANUFACTURING NEW CLAVULAN ACID ETHERS
FR7630455A FR2327776A1 (en) 1975-10-13 1976-10-11 CLAVULANIC ACID DERIVATIVES
GR51905A GR61645B (en) 1975-10-13 1976-10-11 Preparation process of antibacterial agents
CA263,105A CA1081699A (en) 1975-10-13 1976-10-12 Clavulanic acid derivatives
CH1290176A CH629207A5 (en) 1975-10-13 1976-10-12 METHOD FOR PRODUCING CLAVULANINE ACID.
RO7687984A RO69458A (en) 1975-10-13 1976-10-12 PROCESS FOR THE PREPARATION OF CLAVULANIC ACID ETHES
SU762408252A SU656523A3 (en) 1975-10-13 1976-10-12 Method of obtaining clavulanic acid esters or salts thereof
DK457476A DK457476A (en) 1975-10-13 1976-10-12 PROCEDURE FOR THE PREPARATION OF ANTIBACTERIAL ACTIVE SUBSTANCES
LU75980A LU75980A1 (en) 1975-10-13 1976-10-12
HU76BE1340A HU175574B (en) 1975-10-13 1976-10-12 Process for preparing clavulanic acid derivatives
NO763473A NO763473L (en) 1975-10-13 1976-10-12
DE19762646004 DE2646004A1 (en) 1975-10-13 1976-10-12 CLAVULANIC ACID ETHERS, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
FI762908A FI64162C (en) 1975-10-13 1976-10-12 FOERFARANDE FOER FRAMSTAELLNING AV ANTIBAKTERIELLT OCH SOM BETA-LACTAMASINHIBITORER VERKSAMMA ETRAR AV KLAVULANSYRA
JP51122725A JPS5268195A (en) 1975-10-13 1976-10-12 Antiibacterial agent
DD195243A DD127630A5 (en) 1975-10-13 1976-10-12
HU76BE1271A HU173804B (en) 1975-10-13 1976-10-12 Process for preparing clavulanic acid derivatives
YU02516/76A YU251676A (en) 1975-10-13 1976-10-13 Process for obtaining esters of clavulinic acid
BG7634436A BG35466A3 (en) 1975-10-13 1976-10-13 Method for preparing derivatives of clavulanic acid
ES452362A ES452362A1 (en) 1975-10-13 1976-10-13 Clavulanic acid ethers
PL21090176A PL117561B1 (en) 1975-10-13 1976-10-13 Process for preparing novel ethers of clavulanic acid
NL7611286A NL7611286A (en) 1975-10-13 1976-10-13 PROCESS OF PREPARING NEW COMPOUNDS WITH ANTI-BACTERIAL ACTION AND CONTAINING DOSED PHARMACEUTICAL PREPARATIONS.
AR265081A AR213828A1 (en) 1975-10-13 1976-10-13 A PROCEDURE FOR PREPARING CLAVULANIC ACID ETHER DERIVATIVES, ITS ESTERS AND SALTS
ES464123A ES464123A1 (en) 1975-10-13 1977-11-14 Clavulanic acid ethers
ES464122A ES464122A1 (en) 1975-10-13 1977-11-14 Clavulanic acid ethers
AT915178A AT362504B (en) 1975-10-13 1978-12-21 METHOD FOR THE PRODUCTION OF NEW CLAVULAN ACID ETHERS
AT915078A AT362503B (en) 1975-10-13 1978-12-21 METHOD FOR PRODUCING NEW CLAVULANIC ACID ETHERS AND THEIR SALTS
US06/008,421 US4228174A (en) 1975-10-13 1979-02-01 Clavulanic acid ethers
CA338,869A CA1077843A (en) 1975-10-13 1979-10-31 Clavulanic acid derivatives
SE8005662A SE8005662L (en) 1975-10-13 1980-08-11 THE PRODUCTS
SE8005661A SE8005661L (en) 1975-10-13 1980-08-11 PROCEDURE FOR THE PREPARATION OF CLAVULANIC ACID ESTERS
SE8005663A SE8005663L (en) 1975-10-13 1980-08-11 PROCEDURE FOR PREPARING A PHARMACEUTICAL ACTIVE COMPOSITION
DK370780A DK370780A (en) 1975-10-13 1980-08-29 CLAVULANIC ACID DERIVATIVES USED IN THE MANUFACTURE OF ANTIBACTERY ACTIVE SUBSTANCES
DK370680A DK370680A (en) 1975-10-13 1980-08-29 PROCEDURE FOR MANUFACTURING ANTIBACTERY EFFECTIVE ETHERS
US06/278,564 US4609495A (en) 1975-10-13 1981-06-29 Clavulanic acid ethers as antibacterial agents
KE3292A KE3292A (en) 1975-10-13 1983-05-31 Clavulanic acid derivatives
US06/538,767 US4548815A (en) 1975-10-13 1983-10-03 Antibacterial agents
NO833841A NO833841L (en) 1975-10-13 1983-10-21 ANALOGICAL PROCEDURE FOR THE PREPARATION OF CLAVULANIC ACID EATER DERIVATIVES.
NO833842A NO833842L (en) 1975-10-13 1983-10-21 INTERMEDIATE PRODUCTS FOR THE PREPARATION OF CLAVULANIC ACID EATERS
HK489/83A HK48983A (en) 1975-10-13 1983-10-27 Clavulanic acid derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB4189775A GB1565209A (en) 1975-10-13 1975-10-13 Clavulanic acid derivatives

Publications (1)

Publication Number Publication Date
GB1565209A true GB1565209A (en) 1980-04-16

Family

ID=10421864

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4189775A Expired GB1565209A (en) 1975-10-13 1975-10-13 Clavulanic acid derivatives

Country Status (6)

Country Link
BE (1) BE847045A (en)
GB (1) GB1565209A (en)
HU (1) HU175574B (en)
PL (1) PL117561B1 (en)
SU (1) SU656523A3 (en)
ZM (1) ZM11776A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2862385D1 (en) * 1977-08-04 1984-04-12 Beecham Group Plc Process for the preparation of ethers of clavulanic acid
DE2862030D1 (en) * 1977-09-20 1982-11-04 Beecham Group Plc Clavulanic acid derivatives, their preparation and pharmaceutical compositions containing them
DE2862394D1 (en) 1978-01-26 1984-05-03 Beecham Group Plc Derivatives of clavulanic acid, process for their preparation and compositions containing them

Also Published As

Publication number Publication date
HU175574B (en) 1980-09-28
SU656523A3 (en) 1979-04-05
PL117561B1 (en) 1981-08-31
ZM11776A1 (en) 1977-07-21
BE847045A (en) 1977-04-07

Similar Documents

Publication Publication Date Title
US4438101A (en) Antibiotics
US4228174A (en) Clavulanic acid ethers
US4548815A (en) Antibacterial agents
GB1565209A (en) Clavulanic acid derivatives
EP0008877B1 (en) Derivatives of clavulanic acid, a process for their preparation and their use
US4079177A (en) Clavulanic acid carbamates
EP0055062B1 (en) Compounds containing beta-lactams
CA1077843A (en) Clavulanic acid derivatives
US4242262A (en) 9-Nitromethyldeoxyclavulanic acid derivatives preparation and compositions
US4036969A (en) 2,12-Dioxo-7-hydroxymethyl-9-phenyl-1-aza-5,8,11-trioxotetracyclo[9.2.0.06,13 0.6.9 ]tridecane
KR790001313B1 (en) Process for preparation of clavulanio acid
EP0008884B1 (en) Derivatives of clavulanic acid, a process for their preparation and their compositions
CA1149390A (en) Clavulanic acid derivatives, a process for their preparation and their use
EP0008899B1 (en) Clavulanic acid derivatives, their preparation and pharmaceutical compositions containing them
EP0013790B1 (en) Clavulanic acid derivatives, their preparation and pharmaceutical compositions containing them
EP0028083B1 (en) Derivatives of clavulanic acid, a process for their preparation and pharmaceutical compositions containing them
GB1587612A (en) Isoclavulanic acid derivatives
GB1582884A (en) Clavulanic acid derivatives their preparation and use
IE42666B1 (en) Deoxyclavulanic acid and deoxyisoclavulanic acid and derivatives thereof
US4409207A (en) Derivatives of clavulanic acid, a process for their preparation and their use
EP0021836B1 (en) Clavulanic acid derivatives, process for their preparation and pharmaceutical compositions containing them
CS207371B2 (en) Method of preparation of ethers of the clavulane acid
GB1572259A (en) Clavulanic acid derivatives
EP0027324A1 (en) Derivatives of clavulanic acid, processes for their preparation and pharmaceutical compositions containing them
EP0080284A1 (en) Derivatives of clavulanic acid, processes for their preparation and their use

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee